0000000000310275

AUTHOR

Mariantonietta Cicoira

showing 3 related works from this author

Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-AR…

2021

Abstract Aims This sub-study deriving from a multicentre Italian register [Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry (DISCOVER)-ARNI] investigated whether sacubitril/valsartan in addition to optimal medical therapy (OMT) could reduce the rate of implantable cardioverter-defibrillator (ICD) indications for primary prevention in heart failure with reduced ejection fraction (HFrEF) according to European guidelines indications, and its potential predictors. Methods and results In this observational study, consecutive patients with HFrEF eligible for sacubitril/valsartan from 13 Italian centres were included. Lack o…

Left ventricular strainHeart failure; Implantable cardioverter-defibrillator; Left ventricular strain; Remodelling; Sacubitril/valsartanRemodellingHeart failureSacubitril/valsartanHeart failure Implantable cardioverter-defibrillator Left ventricular strain Remodelling Sacubitril/valsartanImplantable cardioverter-defibrillator
researchProduct

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry

2022

Aims: Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR). The aim of this multicenter study was to identify echocardiographic predictors of LVRR after sacubitril/valsartan administration. Methods and results: Patients with HFrEF requiring therapy with sacubitril/valsartan from 13 Italian centres were included. Echocardiographic parameters including LV global longitudinal strain (GLS) and global peak atrial longitudinal strain by speckle tracking echocardiography were measured to find the predictors of LVRR [= LV end-…

EchocardiographyUltrasoundRemodellingHeart failureSacubitril/valsartanBiomarkers Cardiovascular disease Echocardiography Heart failure Imaging Remodelling Sacubitril/valsartan Speckle tracking UltrasoundCardiology and Cardiovascular MedicineCardiovascular diseaseBiomarkers; Cardiovascular disease; Echocardiography; Heart failure; Imaging; Remodelling; Sacubitril/valsartan; Speckle tracking; Ultrasound.BiomarkersImagingSpeckle tracking
researchProduct

Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator…

2010

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide-dependent vasodilation. In 113 patients with chronic heart failure (CHF) and 26 controls, ADMA level was studied in relation to peripheral blood flow and vasodilator capacity. Further, the effects of allopurinol on concentrations of reactive oxygen species (ROS) and ADMA and peripheral vasodilator capacity were tested in a double-blind design. ADMA level was found to be elevated in CHF patients as compared with controls and increased in parallel with New York Heart Association (NYHA) class and exercise capacity (all P < 0.0001). The level of ADMA predicted resting blood flow (P < 0.05) and postischemic vasodilator…

Malemedicine.medical_specialtyHeart diseaseAllopurinolAllopurinolheart failureVasodilationmedicine.disease_causeArgininechemistry.chemical_compoundDouble-Blind Methodendothelial functionInternal medicineMedicineHumansoxidative stressPharmacology (medical)Xanthine oxidaseAgedPharmacologybusiness.industryFree Radical ScavengersMiddle Agedmedicine.diseaseUric AcidVasodilationEndocrinologyCross-Sectional Studieschemistryheart failure; oxidative stress; endothelial functionHeart failureChronic DiseaseUric acidCitrullineFemalebusinessAsymmetric dimethylarginineReactive Oxygen SpeciesOxidative stressmedicine.drug
researchProduct